Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27500646 | 0.97 | HDAC1 (0.52) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL30670303 | 0.90 | CA2 (0.54) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL20370240 | 0.89 | CA2 (0.48) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL15605564 | 0.87 | HDAC1 (0.54) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL11313170 | 0.87 | TDP1 (0.48) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL2166839 | 0.87 | HDAC1 (0.48) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL3857579 | 0.87 | CA2 (0.52) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL11160145 | 0.85 | CHRM1 (0.41) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL6899453 | 0.85 | CA2 (0.66) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL28413287 | 0.84 | HDAC1 (0.44) | HDAC1HDAC2CHRM1CHRM3ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104230981-B | The preparation method of valproic acid phospholipid derivative | JIANGSU NHWA PHARMACEUTICAL CO., LTD. (CN) | 2016-05-18 | — | — | CN | claimed |
| CN-104230981-A | Preparation method of valproic acid phospholipid derivative | JIANGSU NHWA PHARMACEUTICAL CO LTD | 2014-12-24 | — | — | CN | claimed |
| CN-103416943-A | Method and apparatus for quickly cleaning and cleansing hair | LIN BINGSONG | 2013-12-04 | — | — | CN | claimed |
| US-20070219164-A1 | Pharmaceutical compound and method | MEDIPHARMA S.A. (AR) | 2007-09-20 | — | — | US | claimed |
| EP-0202703-B1 | PHARMACEUTICAL COMPOSITIONS OF THE PRODRUG TYPE, A PROCESS FOR THE PREPARATION THEREOF, A PROCESS FOR THE PREPARATION OF THEM AS PRODRUG FUNCTIONING COMPOUNDS AND COMPOUNDS OBTAINED THEREIN | N.V. Gantax Pharmaceutica (BE) | 1989-08-09 | — | — | EP | claimed |
| EP-0202703-A1 | Pharmaceutical compositions of the prodrug type, a process for the preparation thereof, a process for the preparation of them as prodrug functioning compounds and compounds obtained therein | N.V. Gantax Pharmaceutica (BE) | 1986-11-26 | — | — | EP | claimed |
| US-20240216514-A1 | NOVEL ANTITUMOR COMPOUNDS AND RELATED METHODS OF MANUFACTURE AND USE | KLOTHO THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| CN-117414309-B | Ginsenoside composition, daily chemical and application | 茵素科技(广州)有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-116355023-B | Platinum complex containing camptothecine and preparation method and application thereof | 重庆医科大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-116355023-A | Platinum complex containing camptothecine and preparation method and application thereof | 重庆医科大学 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022217255-A1 | NOVEL ANTITUMOR COMPOUNDS AND RELATED METHODS OF MANUFACTURE AND USE | KLOTHO THERAPEUTICS, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-114903028-A | Erythrocyte cryoprotectant and preparation method and application thereof | 华南理工大学 | 2022-08-16 | — | — | CN | disclosed |
| CN-114514264-A | Liquid crystal polyester powder and method for producing liquid crystal polyester solution composition | 住友化学株式会社 | 2022-05-17 | — | — | CN | disclosed |
| EP-0886647-A1 | SERINE PROTEASE INHIBITORS | Akzo Nobel N.V. (NL) | 1998-12-30 | — | — | EP | disclosed |
| WO-1997031937-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-09-04 | — | — | WO | disclosed |
| US-4863965-A | Ibuprofen acid anhydrides and prodrug pharmaceutical composition containing the same | B.V.B.A. INPHARM (BE) | 1989-09-05 | — | — | US | disclosed |
| EP-0202703-B1 | PHARMACEUTICAL COMPOSITIONS OF THE PRODRUG TYPE, A PROCESS FOR THE PREPARATION THEREOF, A PROCESS FOR THE PREPARATION OF THEM AS PRODRUG FUNCTIONING COMPOUNDS AND COMPOUNDS OBTAINED THEREIN | N.V. Gantax Pharmaceutica (BE) | 1989-08-09 | — | — | EP | disclosed |
| EP-0202703-A1 | Pharmaceutical compositions of the prodrug type, a process for the preparation thereof, a process for the preparation of them as prodrug functioning compounds and compounds obtained therein | N.V. Gantax Pharmaceutica (BE) | 1986-11-26 | — | — | EP | disclosed |
| US-4261987-A | ANTICONVULSANTS | GEROT PHARMAZEUTIKA GESELLSCHAFT M.B.H. (AT) | 1981-04-14 | — | — | US | disclosed |
| US-3951995-A | ANTICONVULSANTS, BARBITURATE POTENTIATION | LABORATORIOS MADE, S.A. (ES) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219164-A1 | Pharmaceutical compound and method | GRIK5, PPIP5K2, GRIN2C | HDAC1 61/4885HDAC2 10/4885CHRM1 1792/4885 |
| US-20240216514-A1 | NOVEL ANTITUMOR COMPOUNDS AND RELATED METHODS OF MANUFACTURE AND USE | BID, TBCA, PTBP3 | HDAC1 1082/4885HDAC2 1518/4885CHRM1 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.